Loading...
Market
Will Zenrelia™ capture 20% of the veterinary dermatology market by mid-2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Market research reports and Elanco's public statements
Story
FDA Approves Elanco's Zenrelia™ for Dogs, Shares Up 2%
Sep 19, 2024, 07:18 PM
The U.S. Food and Drug Administration (FDA) has approved Elanco Animal Health's new skin disease treatment for dogs, Zenrelia™ (ilunocitinib tablets). This approval marks a significant advancement in canine dermatology, offering an effective and safe solution for treating skin conditions in dogs. The announcement has positively impacted Elanco's market performance, with the company's shares rising by 2% in afternoon trade.
View original story
Similar markets
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
